Gate2Brain, a spin-off from IRB Barcelona, the University of Barcelona, and the Sant Joan de Déu research Institute devoted to the development of peptide-based delivery technologies for central nervous system diseases, has announced a strategic partnership with Shilpa Biocare Pvt Ltd, a wholly owned subsidiary of Shilpa Medicare Limited.
Shilpa Biocare has become a strategic shareholder in Gate2Brain through a €7 million investment corresponding to a 30.4% equity stake. The partnership represents a major milestone for Gate2Brain and the largest investment raised by the company to date, underscoring the company’s growth and progress in less than six years since its foundation.
G2B-002, Gate2Brain’s lead candidate, is one of the key focuses of the partnership. It is a first-in-class therapeutic candidate for the treatment of aggressive pediatric and adult brain tumours. G2B-002 has received Orphan Drug Designation from both the FDA and EMA.
G2B-002 is based on MiniAp4, Gate2Brain’s proprietary peptide shuttle designed to facilitate drug delivery across the blood-brain barrier, one of the major challenges in diseases of the central nervous system (CNS). Preclinical studies have demonstrated improved drug delivery to the brain and reduced side effects in pediatric brain tumours.
The partnership brings together Gate2Brain’s technology and Shilpa’s expertise in manufacturing, CMC development, and regulatory strategy. Together, the companies aim to accelerate the development of G2B-002 while supporting the expansion of the company’s technology platform into additional therapeutic areas and CNS applications.
This agreement marks a new chapter in the program's development. It also reinforces Gate2Brain's mission to address critical unmet medical needs in pediatric brain cancer and other central nervous system disorders, with the goal of expanding treatment options for patients and their families.
“Gate2Brain acknowledges the continued support of its institutional partners, external advisors, investors, and business angels, whose confidence and commitment have played a key role in advancing the company’s mission and technology platform”, said Dr. Meritxell Teixidó, Gate2Brain's CEO & CSO and an IRB Barcelona alumna.
Gate2Brain is a biotechnology company that was founded in 2020 as a spin-off from IRB Barcelona, the University of Barcelona, and Hospital Sant Joan de Déu Barcelona.
The company is advancing its proprietary technology platform to address high unmet medical needs in pediatric and adult brain tumours, as well as other CNS diseases.
Gate2Brain has received support from leading public and private institutions, including Fundación Botín (Mind the Gap), Banco Sabadell (BStartup Health), CDTI Innovación, the European Innovation Council (EIC Accelerator), ACCIÓ Startup Capital, and Fundación ”la Caixa”.
Shilpa Medicare Limited is a global pharmaceutical company focused on oncology, biologics, complex formulations, and CDMO services.
The company has expertise in manufacturing, regulatory development, and commercialization, serving patients in more than 80 countries worldwide.
Dra. Meritxell Teixidó
CEO y CSO, Gate2Brain
Email: meritxell.teixido@gate2brain.com
Inma Alavedra
Corporate Communications
Email: inma.alavedra@satel-lit.com
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
These nanotubes, thin structures that connect cells to each other, all...
